What are your top takeaways in Hematologic Malignancies from ASCO 2023?

1. S1826 - Randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). AAVD vs. NAVD for advanced stage Hodgkin. Just when we thought outcomes couldn’t get much better, this study showed the superiority of Nivolumab over Brentuximab Ved...

1. SWOG 1826 - cHL study; immediately applicable to patients with cHL > 60
2. ZUMA-7 - OS advantage for 2nd line CAR-T; should lessen barrier to referral to CAR-T
3. POLARIX - Pola R-CHP can safely deliver to advanced-age DLBCL patients; the definition for trial in such a population should be carefully scru...

1. A+AVD vs. N+AVD:
1. Head to head study that looks like it has established a new SOC for patients with advanced stage HL given the improvement in PFS and improved toxicity profile. This is monumental given that just recently A+AVD recently established itself as a SOC with the demonstration of a OS ben...

The presentation linking Agent Orange to MPNs was very interesting. My veteran patients often ask me about this and now we have the first study that shows increased rates of bleeding, thrombosis as well as the risk of developing an MPN with Agent Orange exposure. The zilurgisertib and luspatercept s...

Here are my top 3 acute leukemia abstracts from ASCO 2023:

1. Abstract 7000 by Roddie and others: Top-line results of a pivotal phase Ib/II study of obecabtagene autoleucel (obe-cel), a new CD19-targeted CAR-T cell product for adults with relapsed/refractory B-ALL. Unlike other iterations of CAR-T cel...

The top three lymphoma abstracts were:

1. LBA4: SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)
   The study demonstrates early superiority of nivolumab AVD compared to BV-AVD but also improved toxicity in advance...